What's in Northwell Health's pipeline?

Northwell Health has 9 drugs in our index: 6 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Northwell Health's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/northwell-health.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Northwell Health — Portfolio Competitive Intelligence Brief

Northwell Health pipeline: 6 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Target	Area
Aripriprazole	Aripriprazole	marketed		Other
Heliox	Heliox	marketed		Other
aripiprazole, quetiapine, or risperidone	aripiprazole, quetiapine, or risperidone	marketed
Risperidone microspheres	Risperidone microspheres	marketed
Triiodothyronine	Triiodothyronine	marketed	THAP domain-containing protein 1, Cytochrome P450 2C9, Proliferating cell nuclear antigen	Oncology
Fluoroquinolones	Fluoroquinolones	marketed		Other

Therapeutic area mix

Other · 5
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Northwell Health:

Cite this brief

Drug Landscape (2026). Northwell Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/northwell-health. Accessed 2026-05-16.